The measure of success for 10x Genomics is not the IPO dollar amount, but instead the discoveries made by researchers using its hardware, the CEO said.
Despite recent advances, the world still knows very little about biology, and drug development is still mostly about trial and error due to that lack of understanding. 10x Genomics is building tools that help pierce the veil of complex biology and disease to unlock new possibilities in biomedical research.
These are the ideas that can move the needle. FierceMedTech’s Fierce 15 class of 2018 is aimed at advancement—whether it’s simply combining new know-how with old methods, making definitive improvements in well-trodden fields, or pushing us to reconsider how far we can reach with the means available today.
